EU review timelines suggest that Sandoz, the generics and biosimilar arm of Novartis, could have its Humira biosimilar on the market around that time. Citing NHS figures, Sandoz noted adalimumab ...

The adalimumab segment is the largest revenue contributor to the market. Based on indication, the global biosimilar monoclonal antibodies market is segmented into oncology, autoimmune diseases ...

Hadlima (adalimumab-bwwd), developed by Samsung Bioepis & Organon, follows with 4% of the market as the preferred biosimilar on the US Department of Veterans Affairs national formulary.

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...